On May 26th, Jacek Olczak, CEO of tobacco giant Philip Morris International (PMI), stated in an interview with Agence France-Presse that...
Preventing the sale of conventional cigarettes may boost the public image of Philip Morris, but it will have no impact on the one billion individuals who smoke and can simply purchase a comparable product elsewhere.
Ceasing traditional cigarette sales would add a feather in the cap of PMI but would not affect the one billion smokers worldwide as they can still purchase cigarettes from other companies.
Therefore, instead of discontinuing the sale of cigarettes, he hopes:
If we can persuade governments to permit alternative options, we can accelerate the reduction of cigarette sales.
Persuading governments to allow the emergence of cigarette alternatives would enable PMI to reduce cigarette sales faster.
During the interview, Jacek reiterated that the goal of Fimo International is a "smoke-free future.
Deborah Arnott, the head of the UK non-governmental organization Action on Smoking and Health (ASH), told Agence France-Presse, "We believe that nicotine-containing e-cigarettes can help adult smokers quit smoking, just as the World Health Organization recognizes nicotine replacement therapy." However, Arnott opposes PMI's strong promotion of its new product "because they are still tobacco products and PMI's sole aim is to protect their future income streams.
Philip Morris CEO campaigns for increased sales of heated tobacco. Sources: [none provided]
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
